Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBT-101 in Aviremic HIV-1 Infected Adults
NCT05144386Phase 1Completed
- Sponsor
- Excision BioTherapeutics
- Start
- Jan 2022
- Primary completion
- Nov 2024
- Modality
- Gene Silencing, CRISPR-Cas9, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of EBT-101 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Excision BioTherapeutics. Primary endpoint: Safety and Tolerability of EBT-101 at 48 weeks. Started Jan 2022; status: completed.
02
Drugs
EBT-101
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05144386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144386.